Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Great time to add shares.
This is the time to accumulate shares.
I spoke to Amy from IR yesterday and she said everything's on track.
Buying opportunity.
AMBS. A great time to enter this position. Chart it.
THIS LOOKS LIKE IT'S GOING TO BE A GOOD DAY FOR THE MARKET. FUTURES UP NICELY. AMBS will be moving up.
The Conference call should be great for the stock.
There may be some short covering from shorts that shorted at .18 and can now lock in a profit.
Tomorrow is a great day to buy some stock. More NEWS is coming.
So Jobogie didn't take that .15 bet with you. Do you still see AMBS at .15 by labor day.
Rght now is a great time to add to your position.
Yeah. That Lympro revenue projection wil be good for the stock.
Soon everybody will know who AMBS is when they're traded on the NASDAQ.
I believe this is heading to .12 plus tomorrow.
Here comes the run. Grab those cheap shares. Kaboom time.
WE MAY HIT .20 TODAY.
WATCH FOR A GAP UP ON THE OPEN.
I agree. .25 coming shortly imo.
500 million dollar market cap when we trade on the NASDAQ.
We may trade back to .20 today. Grab the cheapies quickly imo.
Bid stacking. Today we run.
This stock will be up 30% imo.
Once AMBS gets to the NASDAQ institutional buyers will come in aka BIG MONEY.
The market cap will quickly go to 500 Million on the NASDAQ.
HEADING TO A NEW 52 WEEK HIGH. .25 is coming.
AMBS going to the NASDAQ.
AMBS going to the NASDAQ.
I think we'll be up 30% today. Proportional reverse split is a genius move to get to the NASDAQ quickly. Now just pay attention to market cap.
I agree. .25 by week's end.
AMBS going to the NASDAQ. Today we rally.
Gerald is a genious.
Amarantus believes the market opportunity for an effective Alzheimer's disease blood diagnostic such as LymPro far exceeds $500 million annually in the United States alone, and the Company intends to be first to market with a biologically relevant diagnostic blood test for Alzheimer's.
Hold your shares tight. I believe Gerald has something very big in the partnership area coming.
Do you still see .15 by labor day?
Obviously you do not know anything about this company.
Lympro partnership is what I'm here for.
It will take 9 years for AMBS to need fda approval.
Don't forget the Lympro partnership. They can potentially bring manufacturing of Lympro on a major scale.
Gerald posted on Twitter there's going to b news this week. I agree with Solantey. .15 coming soon. Hold those shares tight.
Hold for the gold. Gerald has something up his sleeve.
LYMPRO is a 500 million dollar a year opportunity according to the company. When the revenues start flowing and the partnership news is made public AMBS will trade at .50 imo.
Dr. Commissiong has served as the Chief Scientific Officer and a Director of Amarantus since co-founding the company in 2008. Prior to Amarantus, Dr. Commissiong served as the CSO of Neurotrophics, Inc. and Prescient Neuropharma, Inc. Throughout his distinguished career, Dr. Commissiong has been focused on the discovery of novel neurotrophic factors for the treatment of neurodegenerative diseases as well as understanding the fundamental underlying biology of protoplasmic type-1 astrocytes that secrete neurotrophic factors. He was Chief of the Neural Transplantation Unit, NINDS-NIH, from 1989-94 where his research focused on identifying therapeutic approaches to spinal cord injury. Dr. Commissiong was Head of the Neurotrophic Factors Group, NINDS-NIH, from 1994-97 where he focused on developing technologies to systematically identify novel neurotrophic factors with applications for specific Central Nervous System disorders. He co-founded Prescient Neuropharma in 1999, and discovered MANF in 2003. MANF is currently in preclinical development for the treatment of Parkinson’s disease. The work pioneered by Dr. Commissiong has led to significant advancements in the field of astrocyte-neuron biology. Dr. Commissiong believes that a fundamental understanding of astrocyte-neuron interactions in the Central Nervous System will lead to a new generation of therapies to treat brain-related disorders.
Dr. Commissiong did his Postdoctoral work in the Lab Preclin Pharmac, NIMH-NIH, concentrating on the application of quadrupole mass spectrometry in the analysis of neurotransmitters. He holds a Ph.D. in Neurophysiology from the University of Southampton, an M.Sc. in Biochemical Pharmacology from the University of Southampton, and a B.S. in Biology and Chemistry from the University of the West Indies.
- See more at: http://www.thechairmansblog.com/amarantus-bioscience/management/#sthash.KDNRb7nz.dpuf
The company doesn't promote its stock that I have seen.
I'll bet you the stock price is up by the end of the week.
By the end of the year my friend.
THE COMPANY HAS STATED LYMPRO IS A 500 MILLION DOLLAR A YEAR OPPORTUNITY.
.15 cents by the end of the week.I smell NEWS.